GenBioPro
Private Company
Funding information not available
Overview
GenBioPro is a mission-driven generic pharmaceutical company focused on reproductive health, specifically on improving access to medical abortion care. Its flagship product is the first and only FDA-approved generic version of mifepristone, a key medication used in combination with misoprostol for terminating early pregnancy. The company's strategy combines commercial activity with legal and regulatory advocacy to reshape the accessibility landscape, having successfully advocated for changes to FDA dispensing requirements. GenBioPro positions itself as a stabilizing force for supply and a catalyst for price reduction in a politically and legally volatile market.
Technology Platform
Generic drug development and manufacturing, integrated with legal and regulatory advocacy to expand market access.
Opportunities
Risk Factors
Competitive Landscape
GenBioPro's direct competitor is Danco Laboratories, the distributor of the branded version Mifeprex. The competition is primarily on price and supply assurance. The broader competitive and adversarial landscape includes political actors, state legislatures, and advocacy groups seeking to restrict abortion access, which indirectly target the company's market. Pro-access advocacy groups and telehealth providers are key allies in expanding the ecosystem.